science

Mirikizumab

Mirikizumab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Mirikizumab rather than just read about it. In short: Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity.

Key takeaways

Mirikizumab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Mirikizumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Mirikizumab from memory before moving on to harder problems.

Reference excerpt

Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity. The most common side effects include upper respiratory tract infections (nose and throat infections), headache, rash and reactions at the site of injection (when given by injection under the skin). Mirikizumab was approved for medical use in the European Union in May 2023, and in the United States in October 2023.

Medical uses In the European Union, mirikizumab is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. In the United States, mirikizumab is indicated for the treatment of adults with moderately to severely active ulcerative colitis. In January 2025, the US Food and Drug Administration (FDA) expanded the indication for mirikizumab to include the treatment of moderately to severely active Crohn's disease in adults.

History Mirikizumab was developed by Eli Lilly and Company. The approval was based on the LUCENT 1 clinical study which evaluated the safety and efficacy of mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC. All participants enrolled in the program had a diagnosis of UC for at least three months prior to baseline and a confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS). After twelve weeks of induction treatment, 24% of participants on mirikizumab achieved clinical remission, which compared with 15% for those on a placebo. During the maintenance phase, 66% of mirikizumab takers who had achieved remission at twelve weeks stayed in remission through one year of treatment. Among those who achieved clinical response at twelve weeks, 51% of all mirikizumab-treated participants remained in clinical remission at one year, compared to 27% of those on placebo. Additionally, 99% who achieved clinical remission at one year were steroid-free, and 39% had achieved resolution or near resolution of bowel urgency, which is reported by UC participants as one of the most disruptive symptoms of the condition.

Society and culture

Legal status In 2023, mirikizumab was approved as a first-in-class treatment for adults with moderately to severely active ulcerative colitis in Japan; however, approval in the United States has not been granted due to manufacturing issues. In March 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Omvoh, intended for the treatment of ulcerative colitis. The applicant for this medicinal product is Eli Lilly Nederland B.V. Mirikizumab was approved for medical use in the European Union in May 2023. Mirikizumab was approved for medical use in the United States in October 2023.

Names Mirikizumab is the international nonproprietary name.

References

Worked examples

Example 1 — a first encounter with Mirikizumab

Start with the simplest possible case. Write down what Mirikizumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Mirikizumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Mirikizumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Mirikizumab

In research: Mirikizumab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Mirikizumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Mirikizumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Mirikizumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Mirikizumab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Mirikizumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Mirikizumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Mirikizumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Mirikizumab in simple terms?

Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity.

Why does Mirikizumab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Mirikizumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Mirikizumab.